Leukotriene B₄ Metabolism and p70S6 Kinase 1 Inhibitors: PF-4708671 but Not LY2584702 Inhibits CYP4F3A and the ω-Oxidation of Leukotriene B₄ In Vitro and In Cellulo

Anne-Sophie Archambault¹,², Caroline Turcotte¹,², Cyril Martin¹, Julie S. Lefebvre¹, Véronique Provost¹, Michel Laviolette¹,², Nicolas Flamand¹,²*

¹ Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Québec City, Québec, Canada, ² Département de médecine, Faculté de médecine, Université Laval, Québec City, Québec, Canada

* Nicolas.Flamand@criucpq.ulaval.ca

Abstract

LTB₄ is an inflammatory lipid mediator mainly biosynthesized by leukocytes. Since its implication in inflammatory diseases is well recognized, many tools to regulate its biosynthesis have been developed and showed promising results in vitro and in vivo, but mixed results in clinical trials. Recently, the mTOR pathway component p70S6 kinase 1 (p70S6K1) has been linked to LTC₄ synthase and the biosynthesis of cysteinyl-leukotrienes. In this respect, we investigated if p70S6K1 could also play a role in LTB₄ biosynthesis. We thus evaluated the impact of the p70S6K1 inhibitors PF-4708671 and LY2584702 on LTB₄ biosynthesis in human neutrophils. At a concentration of 10 μM, both compounds inhibited S6 phosphorylation, although neither one inhibited the thapsigargin-induced LTB₄ biosynthesis, as assessed by the sum of LTB₄, 20-OH-LTB₄, and 20-COOH-LTB₄. However, PF-4708671, but not LY2584702, inhibited the ω-oxidation of LTB₄ into 20-OH-LTB₄ by intact neutrophils and by recombinant CYP4F3A, leading to increased LTB₄ levels. This was true for both endogenously biosynthesized and exogenously added LTB₄. In contrast to that of 17-octadecynoic acid, the inhibitory effect of PF-4708671 was easily removed by washing the neutrophils, indicating that PF-4708671 was a reversible CYP4F3A inhibitor. At optimal concentration, PF-4708671 increased the half-life of LTB₄ in our neutrophil suspensions by 7.5 fold, compared to 5 fold for 17-octadecynoic acid. Finally, Michaelis-Menten and Line-weaver-Burk plots indicate that PF-4708671 is a mixed inhibitor of CYP4F3A. In conclusion, we show that PF-4708671 inhibits CYP4F3A and prevents the ω-oxidation of LTB₄ in cellulo, which might result in increased LTB₄ levels in vivo.

Introduction

Leukotrienes (LT) are inflammatory lipid mediators derived from arachidonic acid. They participate in the inflammatory cascade in numerous conditions, notably asthma, rheumatoid
Arthritis, allergies and in host defense [1, 2]. They are mainly biosynthesized by leukocytes via the 5-lipoxygenase (5-LO) pathway. With the help of its activating protein, 5-LO metabolizes arachidonic acid into the unstable intermediate LTA₄. LTA₄ can subsequently be metabolized into LTB₄ by the LTA₄ hydrolase, or into LTC₄ by the LTC₄ synthase. Cysteinyl-LTs are well known for their role in asthma and bronchoconstriction, while LTB₄ is more involved in leukocyte recruitment and activation. In humans, LTB₄ can be further metabolized into 12-oxo-LTB₄ by the LTB₄ 12-hydroxydehydrogenase, or it can be ω-oxidized by the CYP4F3A [3–5]. The latter, which is mainly expressed in neutrophils, catalyzes the formation of 20-OH-LTB₄, then 20-COOH-LTB₄.

The recognized implication of LTB₄ in inflammation makes it an attractive therapeutic target. However, the inhibition of LTB₄ biosynthesis showed mixed results in clinical trials, despite promising results in mice models of inflammatory diseases [1, 2]. Among the numerous compounds tested, only the 5-LO inhibitor Zileuton has been approved as a treatment for asthma. Therefore, a better understanding of LTB₄ metabolism and its regulation could lead to new therapeutic approaches.

Two recent studies linked the mTOR pathway component p70S6 kinase 1 (p70S6K1) to LTC₄ biosynthesis, showing that p70S6K1 could phosphorylate the LTC₄ synthase, hence modulating its activity [6, 7]. Herein, we sought to determine whether p70S6K1 could also modulate LTB₄ biosynthesis and metabolism. We thus evaluated the impact of two selective p70S6K1 inhibitors, PF-4708671 [8] and LY2584702 [9], on the biosynthesis of LTB₄ and its metabolites in human neutrophils.

Materials and Methods

Material

Lymphocyte separation medium, aprotinin, dimethyl sulfoxide (DMSO) and solvents for HPLC and LC/MS were purchased from Thermo Fisher Scientific (Ottawa, Ontario, Canada). Dextran, adenosine deaminase, leupeptin and potassium phosphate were obtained from Sigma-Aldrich Canada (Oakville, Ontario, Canada). HBSS was purchased from Wisent Bioproducts (St-Bruno, Quebec, Canada). 19-OH-prostaglandin (PG) B₂, PGB₂, PGB₂-D₄ and 17-octadecynoic acid (17-ODYA) were purchased from Cayman Chemicals (Ann Arbor, Michigan, USA). PF-4708671 was obtained from Abcam (Cambridge, Massachusetts, USA) and LY2584702 from Selleckchem (Houston, Texas, USA). Thapsigargin was obtained from Tocris Bioscience (Ellisville, Missouri, USA). LTB₄ was a generous gift from Dr Louis Flamand (Université Laval, Québec City, Canada). Recombinant CYP4F3A and the NADPH regenerating system were purchased from Corning (Corning, New York, USA). Protease and phosphatase inhibitor cocktail tablets were purchased from Roche (Laval, Quebec, Canada). Primary (anti-phospho-S6 #2211 and anti-S6 #2317) and secondary antibodies were obtained from Cell Signaling (Danvers, Massachusetts, USA). The enhanced chemiluminescent (ECL) substrate was obtained from Millipore Canada Ltd (Toronto, Ontario, Canada).

Preparation and utilization of adenosine deaminase

Adenosine deaminase was prepared and utilized exactly as described before [10].

Isolation of human neutrophils and cell stimulations

Human neutrophils were isolated from the peripheral blood of healthy volunteers, without consideration for gender, as described before [11]. For the experiments investigating the impact of p70S6 kinase inhibitors on LTB₄ biosynthesis and LTB₄ half-life, pre-warmed
human neutrophil suspensions (37˚C, 5 million cells/ml in HBSS containing 1.6 mM CaCl₂) were incubated with PF-4708671, LY2584702 or vehicle (DMSO) for 5 minutes, then stimulated with 100 nM thapsigargin for 10 minutes or 1 μM LTB₄ for different times (see Figures). For experiments in which the reversibility of PF-4708671 and 17-ODYA were assessed, pre-warmed human neutrophil suspensions were incubated with PF-4708671, 17-ODYA or vehicle (DMSO) for 5, 15 or 30 minutes. Cells were centrifuged (350 × g) and the pellets were suspended in HBSS-CaCl₂ or autologous plasma for 20 minutes. Cells were washed 3 times with warm HBSS-CaCl₂ before adding 1 μM LTB₄ for 20 minutes.

Analysis of LTB₄ and its ω-oxidation products

Incubations were stopped by adding 1 volume of a cold (-30˚C) stop solution (MeOH/MeCN, 1/1, v/v) containing 12.5 ng of both 19-OH-PGB₂ and PGB₂ as internal standards. The samples were placed at -30˚C overnight to allow protein denaturation and then centrifuged (1000 × g, 10 minutes, 4˚C). The resulting supernatants were analyzed by reversed-phase HPLC using a Shimadzu HPLC System (Shimadzu corporation, Kyoto, Japan) and an on-line extraction procedure based on a method from Borgert et al [12]. In brief, samples were diluted 1/3 with water, then injected and loaded onto a C8 precolumn (Aquapore Octyl 7 μM, PerkinElmer, Waltham, USA) using water containing 0.01% phosphoric acid during 4.25 minutes. The C8 precolumn was then switched on-line with the HPLC analytical column (Accucore™ C18, 50 × 4.6 mm, 2.6 μm, ThermoFisher Scientific, Ottawa, Canada) and elution was performed using a discontinuous binary gradient with solvent A and solvent B. Solvent A consisted of MeOH/MeCN/H₂O at a 44/11/45 ratio (v/v/v) plus 0.01% AcOH and DMSO. Solvent B consisted of MeOH/MeCN/H₂O at a 63/32/5 ratio (v/v/v) plus 0.01% AcOH. The gradient was: 0–15% B from 4.25 to 5.25 minutes; 15–70% B from 5.25 to 12 minutes; 70–100% B from 12 to 12.30 minutes and held at 100% during 4 minutes. Column then was re-equilibrated into 15% solvent B during 5 minutes before the next sample was injected. Using this method, the retention times were 5.3 minutes for 19-OH-PGB₂, 6.4 minutes for 20-COOH-LTB₄, 6.7 minutes for 20-OH-LTB₄, 8.9 minutes for PGB₂, 9.8 minutes for 6Z-LTB₄, 9.9 minutes for 6Z-12epi-LTB₄, 10.1 minutes for LTB₄, and 12.5 minutes for 5-HETE. Internal standards and LTs were detected by UV at 270 nm while 5-HETE was detected at 235 nm. Leukotrienes represent the sum of LTB₄, 20-OH-LTB₄ and 20-COOH-LTB₄.

In vitro CYP4F3A assay

Human recombinant CYP4F3A (5 pg/ml) in potassium phosphate buffer (100 mM, pH 7.4) containing a NADPH generating system (glucose-6-phosphate, NADP+, glucose-6-phosphate dehydrogenase, MgCl₂) was warmed at 37˚C then incubated for 5 minutes with inhibitors or vehicle (DMSO). LTB₄ (1-20 μM) then was added and reactions were stopped at different times with 5 volumes of a cold stop solution. LTB₄ and its ω-oxidation products were quantified by HPLC as described in methods. The initial reaction rate for each LTB₄ concentration was determined. The maximal velocity (vₚₑₘₐₓ) and the Michaelis-Menten constant (Kₘ) were calculated for each concentration of PF-4708671 to assess the type of inhibition, using non-linear regression of the Michaelis-Menten graph with the Graphpad Prism 7 Software (GraphPad Software, Inc., La Jolla, California, USA). The Michaelis-Menten graph was also linearized using the Lineweaver-Burk (double reciprocal) plot.

Immunoblot

Pre-warmed neutrophil suspensions (37˚C, 5 million cells/ml in HBSS containing 1.6 mM CaCl₂) were stimulated with 100 nM of thapsigargin or N-Formylmethionine-leucyl-
phenylalanine (fMLP) for 5 minutes. PF-4708671, LY2584702 or vehicle were added 5 minutes before stimulation. Incubations were stopped using 1 volume of cold (4˚C) incubation buffer. The suspensions were centrifuged (350 x g, 5 min, 4˚C) and then lysed in a cold (4˚C) hypotonic buffer (10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl2, 1 mM EDTA, pH 7.4) containing 0.1% NP-40, protease inhibitors (10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 mM PMSF, protease inhibitor cocktail tablets), 2 mM diisopropyl fluorophosphate (DFP) and phosphoSTOP. Cells were vortexed for 15 seconds, then immediately solubilized in electrophoresis sample buffer (62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 0.01% bromophenol blue, 5% β-mercaptoethanol, 2% SDS) and boiled for 10 minutes. Proteins were loaded on a 12% polyacrylamide gel for electrophoresis, and transferred onto a PVDF membrane. Membranes were blocked using TBS/Tween buffer containing 5% w/v skim milk and incubated overnight at 4˚C with primary antibodies (anti-phospho-S6 #2211 and anti-S6 #2317, Cell Signaling) in TBS/Tween containing 5% skim milk. HRP-linked secondary antibodies and ECL substrate were used for detection.

Quantification of PF-4708671 by LC-MS/MS

Incubations were stopped by adding one volume of cold (-30˚C) MeOH + 0.01% acetic acid containing 2 ng of PGB2-D4 as an internal standard. The samples were placed at -30˚C overnight to allow protein denaturation and then centrifuged (1000 × g, 10 minutes). The resulting supernatants were collected and diluted with water + 0.01% acetic acid to obtain a final MeOH concentration ≤ 10%. Lipids were extracted from the samples using solid phase extraction cartridges (Strata-X Polymeric Reversed Phase, 60 mg/1ml, Phenomenex). The eluate was dried under a stream of nitrogen and reconstituted in 50 μl of MeOH. 1 μl was injected onto an HPLC column (Kinetex C8, 150 × 2.1 mm, 2.6 μm, Phenomenex) and eluted at a flow rate of 500 μl/min with a linear gradient using 0.1% formic acid (solvent A) and acetonitrile containing 0.1% formic acid (solvent B). The gradient lasted 20 minutes, starting at 10:90 (A:B) a finishing at 90:10 (A:B). The HPLC system was interfaced with the electrospray source of a Shimadzu 8050 triple quadrupole mass spectrometer and mass spectrometric analysis was done in the negative ion mode using multiple reaction monitoring for the specific mass transition m/z 389.10 → 197.95.

Statistical analyses

Data are represented as the mean ± S.D. All calculations were done using the Graphpad Prism 7 Software.

Ethics

This study was approved by the local ethics committee (Comité d’éthique de la recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec) and all subjects signed a consent form.

Results

p70S6 kinase 1 inhibitors do not inhibit the biosynthesis of LTB4 but PF-4708671 prevents further LTB4 metabolism

In the first series of experiments, we investigated whether p70S6K1 inhibitors modulated LTB4 biosynthesis. As shown in Fig 1A, PF-4708671 and LY2584702 at a concentration of 10 μM did not stimulate nor inhibit the thapsigargin-induced LTB4 biosynthesis. At this concentration, both compounds inhibited the phosphorylation of S6 induced by thapsigargin or fMLP (Fig 1B), indicating that they were both efficiently inhibiting the p70S6K1. However, we
noticed that 10 μM PF-4708671 prevented the metabolism of LTB₄ into 20-OH-LTB₄ and 20-COOH-LTB₄ in thapsigargin-stimulated neutrophils with an IC₅₀ of ~800 nM (Fig 1C). This led to a decrease in 20-OH- and 20-COOH-LTB₄ levels, and an increase in LTB₄ levels. In contrast, LY2584702 did not prevent the metabolism of LTB₄ into 20-OH- and 20-COOH-LTB₄ (Fig 1D).

We next determined if PF-4708671 could also inhibit the degradation of exogenously added LTB₄ to 20-OH- and 20-COOH-LTB₄ by performing kinetic experiments in which neutrophils were incubated with 1 μM LTB₄. PF-4708671 increased the half-life of LTB₄ by 7.5 fold, from ~20 minutes to ~150 minutes (Fig 2A). In contrast, LY2584702 did not significantly modulate LTB₄ half-life (Fig 2B). In comparison, the CYP4F3A inhibitor 17-ODYA, previously shown to inhibit the metabolism of LTB₄ into 20-OH-LTB₄ in human neutrophils [13], increased LTB₄ half-life by 5 fold, from ~10 minutes to ~50 minutes (Fig 2C). In these experiments, neutrophils were treated with PF-4708671 and 17-ODYA during 5 and 30 minutes.
respectively before the addition of LTB₄. This is because PF-4708671 exerted its inhibitory constraint almost instantaneously while the optimal inhibitory effect of 17-ODYA was observed after 30 minutes (Fig 2D). Of note, the conversion of LTB₄ into 20-OH- and 20-COOH-LTB₄ only occurred when neutrophils were present in the incubation media (Fig 2E). Indeed, LTB₄ was not transformed into ω-LTB₄ in our incubation medium (HBSS) or in a neutrophil supernatant, but was efficiently ω-oxidized in neutrophil suspensions, supporting the fact that the ω-oxidation of LTB₄ is an intracellular event.

PF-4708671 is a mixed inhibitor of CYP4F3A

The distinct inhibitory profiles of PF-4708671 and LY2584702 on LTB₄ metabolism raised the possibility that PF-4708671 was a CYP4F3A inhibitor. We thus tested this hypothesis by comparing the effect of p70S6K1 inhibitors with the CYP4F3A inhibitor 17-ODYA on human recombinant CYP4F3A activity. Human recombinant CYP4F3A was incubated with increasing concentrations of PF-4708671 or 17-ODYA for 5 and 30 minutes respectively, before the addition of 1 μM of LTB₄ for 1 minute. PF-4708671 induced a concentration-dependent inhibition of ω-oxidation product formation (IC₅₀ ~750 nM) while LY2584702 poorly affected this enzymatic conversion (Fig 3A). In other experiments, CYP4F3A was treated with increasing concentrations of PF-4708671 before the addition of various LTB₄ concentrations. We then calculated the maximal rate of the reaction (v_max) and the Michaelis-Menten constant (K_M) during the steady-state of the reaction using the non-linear regression of the Michaelis-Menten graph. The representation of the data using either the Michaelis-Menten graph (Fig 3C) or the...
Lineweaver-Burk plot (Fig 3D) are consistent with a model of mixed inhibition. This mixed inhibition indicated that PF-4708671 was perhaps a substrate of CYP4F3A. However, LC-MS/MS analyses of PF-4708671 levels indicated that the compound remained stable in our neutrophil suspensions and in our enzymatic assay with recombinant CYP4F3A for up to 2 hours (data not shown).

The inhibitory effect of PF-4708671 on LTB4 ω-oxidation is reversible

Finally, we assessed if the inhibitory effect of PF-4708671 was reversible by comparing it with the irreversible CYP4F3A inhibitor 17-ODYA [13]. In these experiments, neutrophils were incubated with PF-4708671 for 5 minutes or 17-ODYA for 30 minutes (optimal incubation times) or with the inhibitors for 15 minutes (comparable incubation time). Then, neutrophils were either washed with HBSS-CaCl2, washed with autologous plasma or not washed at all, before treatment with either 100 nM thapsigargin or 1 μM LTB4. In absence of washing, both PF-4708671 and 17-ODYA inhibited the metabolism of LTB4 into 20-OH- and 20-COOH-LTB4 (Fig 4). Washing the PF-4708671-treated neutrophils with either HBSS-CaCl2 or autologous plasma restored the ability of neutrophils to metabolize endogenously formed and exogenously added LTB4 into 20-OH- and 20-COOH-LTB4 (Fig 4A–4C). In contrast, 17-ODYA-treated neutrophils that were washed with either HBSS-CaCl2 or
autologous plasma remained incapable of metabolizing endogenously biosynthesized or exogenously added LTB₄ into 20-OH- or 20-COOH-LTB₄ (Fig 4D–4F). Furthermore, similar results were obtained whether we used the optimal incubation time for each inhibitor or the comparable incubation time (5 and 30 minutes for PF-4708671 vs. 15 minutes for each inhibitor). These experiments indicate that in contrast to the irreversible inhibitor 17-ODYA, the inhibitory constraint of PF-4708671 is easily removable and that the latter is a reversible inhibitor of the CYP4F3A enzyme.

**Discussion**

Two recent studies have linked the mTOR pathway component p70S6K1 to LTC₄ synthase function, providing a possible new way of regulating cysteinyl-LT biosynthesis [6, 7]. Thus, we wondered if p70S6K1 could play a similar role in the regulation of LTB₄ synthesis. In that regard, our data show that 1) the thapsigargin-induced LTB₄ biosynthesis is not inhibited by p70S6K1 inhibitors; 2) PF-4708671, but not LY2584702, inhibits the metabolism of LTB₄ into 20-OH- and 20-COOH-LTB₄ (Fig 4D–4F). Furthermore, similar results were obtained whether we used the optimal incubation time for each inhibitor or the comparable incubation time (5 and 30 minutes for PF-4708671 and 17-ODYA vs. 15 minutes for each inhibitor). These experiments indicate that in contrast to the irreversible inhibitor 17-ODYA, the inhibitory constraint of PF-4708671 is easily removable and that the latter is a reversible inhibitor of the CYP4F3A enzyme.

Fig 4. Removal of the inhibitory constraint exerted by CYP4F3A inhibitors on LTB₄ ω-oxidation in neutrophils. Pre-warmed human neutrophil suspensions (37°C, 5 million cells/ml in HBSS containing 1.6 mM CaCl₂) were incubated with A,B) 30 μM PF-4708671 or vehicle for 5 minutes, C) 30 μM PF-4708671 for 15 minutes, D,E) 30 μM 17-ODYA for 30 minutes, or F) 30 μM 17-ODYA for 15 minutes. Neutrophils were washed (or not) with autologous plasma or HBSS-CaCl₂ as described in methods. A,D) 100 nM thapsigargin or B,C,E,F) 1 μM LTB₄ were then added for 10 and 20 minutes, respectively. Samples then were processed and analyzed for 20-OH-LTB₄ and 20-COOH-LTB₄ as described in methods. Data are the mean (± S.D) of 4 independent experiments, each performed in duplicate.

doi:10.1371/journal.pone.0169804.g004
In this study, we aimed at documenting the inhibitory effect of p70S6K1 inhibitors on the ability of human neutrophils to metabolize LTB₄ into 20-OH- and 20-COOH-LTB₄. For that reason, we utilized an experimental model in which the priming of the arachidonic acid cascade and the 5-LO pathway were not involved, i.e. thapsigargin-stimulated neutrophils. In that experimental model, we could show that the ability of neutrophils to biosynthesize LTB₄, which includes the sum of LTB₄, 20-OH-LTB₄, and 20-COOH-LTB₄, was unchanged. This indicates that at the concentration utilized, the p70S6K1 inhibitors PF-4708671 and LY2584702 did not inhibit the enzymes involved in LTB₄ biosynthesis in human neutrophils, notably cPLA₂α, 5-LO, 5-LO-activating protein and LTA₄ hydrolase [14–17]. However, it remains possible that the p70S6K1 inhibitors used in this study might impact LTB₄ biosynthesis in human neutrophils when other signaling mechanisms are involved, notably those linked to the priming of LTB₄ biosynthesis such as cytokines and TLR activation [18, 19], raising the possibility that PF-4708671, and possibly LY2584702, modulate LT biosynthetic pathways through multiple mechanisms of action.

We found that PF-4708671, but not LY2584702, inhibited the metabolism of LTB₄ into 20-OH- and 20-COOH-LTB₄ in a concentration-dependent manner. In that regard, PF-4708671 was more potent than 17-ODYA, a recognized CYP4F3A inhibitor [13]. Moreover, the effect of PF-4708671 was more pronounced than that of 17-ODYA. While PF-4708671 increased the half-life of LTB₄ in our human neutrophil suspensions by 7.5 fold, 17-ODYA increased it by 5 fold. This indicates that PF-4708671 might be a promising tool to develop specific and potent inhibitors of the CYP4F3A enzyme.

Given that the Michaelis-Menten and the Lineweaver-Burk plots indicated that PF-4708671 was a mixed inhibitor, we thought that perhaps PF-4708671 was a CYP4F3A substrate and was metabolized to some extent by the enzyme. However, this hypothesis was proven incorrect, as PF-4708671 was stable for at least 2 hours in the presence of either recombinant CYP4F3A or human neutrophils. The mixed inhibition we observed also raised the possibility that a contaminant in our commercial PF-4708671 preparation might also inhibit CYP4F3A. Although we cannot infirm that possibility, we tested three different batches of PF-4708671 which all yielded the same results, indicating that the effects we are documenting are very unlikely to be caused by a compound that is present in trace amounts.

This is not the first study to underscore a non-specific effect of PF-4708671. Another group reported an off-target effect of PF-4708671 in immortalized mouse fibroblasts, showing that PF-4708671 activates AMPK and inhibits the mitochondrial respiratory chain complex I, independently of p70S6K1 [20]. Moreover, PF-4708671 is used as a tool to study the mTOR pathway in various in vivo and in vitro studies, mainly in models of type 2 diabetes and cancer [21–33]. In light of our findings, it cannot be ruled out that some of the previously reported effects of PF-4708671 are caused by its lack of specificity and possibly increased LTB₄ levels.

It was previously reported that LTB₄ levels are increased in white adipose tissue, liver and muscles of mice fed with an high fat diet [34, 35]. Furthermore, mice lacking LTB₄ receptor 1 are less susceptible to diet-induced insulin resistance [36, 37]. Therefore, using PF-4708671 in models of type 2 diabetes could increase LTB₄ levels and possibly lead to an increased inflammation. However, in rodents, the functional orthologue of CYP4F3A is CYP4F18, which transforms LTB₄ into 18-OH-LTB₄ instead of 20-OH-LTB₄ [38, 39]. While the activity of CYP4F18 towards LTB₄ has been characterized, it is still unknown whether PF-4708671 exerts an inhibitory effect on CYP4F18 as well.

In conclusion, we demonstrate that PF-4708671 is a reversible CYP4F3A inhibitor preventing the metabolism of LTB₄ into 20-OH- and 20-COOH-LTB₄. In addition to characterizing a new compound that induces a sustained elevation in LTB₄ levels, our data shed some light on the non-specific effects of a widely used p70S6K1 inhibitor. Given that it is more potent than
the only currently available CYP4F3A inhibitor, PF-4708671 might be an helpful tool for the development of potent CYP4F3A inhibitors to study the regulation of LTB\(_4\) metabolism and its impact in inflammation.

Supporting Information
S1 Appendix.
(XLSX)

Acknowledgments
ML and NF are members of the inflammation group of the Respiratory Health Network of the Fonds de recherche du Québec-Santé.

Author Contributions
Conceptualization: ASA JSL VP ML NF.
Formal analysis: ASA NF.
Funding acquisition: ML NF.
Investigation: ASA CM NF.
Methodology: ASA CM NF.
Resources: ML NF.
Supervision: ML NF.
Visualization: ASA NF.
Writing – original draft: ASA CT NF.
Writing – review & editing: ASA CT CM JSL VP ML NF.

References
1. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med. 2007; 357(18):1841–54. doi: 10.1056/NEJMra071371 PMID: 17978293
2. Flamand N, Mancuso P, Serezani CH, Brock TG. Leukotrienes: mediators that have been typecast as villains. Cell Mol Life Sci. 2007; 64(19–20):2657–70. doi: 10.1007/s00018-007-7228-2 PMID: 17639273
3. Soberman RJ, Harper TW, Murphy RC, Austen KF. Identification and functional characterization of leukotriene B\(_4\) 20-hydroxylase of human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A. 1985; 82(8):2292–5. PMID: 2986111
4. Kikuta Y, Kusunose E, Endo K, Yamamoto S, Sogawa K, Fujii-Kuriyama Y, et al. A novel form of cytochrome P-450 family 4 in human polymorphonuclear leukocytes. cDNA cloning and expression of leukotriene B\(_4\) omega-hydroxylase. J Biol Chem. 1993; 268(13):9376–80. PMID: 8468631
5. Yokomizo T, Ogawa Y, Uozumi N, Kume K, Izumi T, Shimizu T. cDNA cloning, expression, and mutagenesis study of leukotriene B\(_4\) 12-hydroxydehydrogenase. J Biol Chem. 1996; 271(5):2844–50. PMID: 8576264
6. Esser J, Gehrmann U, Salvado MD, Wetterholm A, Haeggstrom JZ, Samuelsson B, et al. Zymosan suppresses leukotriene C\(_4\) synthase activity in differentiating monocytes: antagonism by aspirin and protein kinase inhibitors. FASEB J. 2011; 25(4):1417–27. doi: 10.1096/fj.10-175828 PMID: 21228223
7. Ahmad S, Ytterberg AJ, Thulasingam M, Tholander F, Bergman T, Zubarev R, et al. Phosphorylation of Leukotriene C\(_4\) Synthase at Serine 36 Impairs Catalytic Activity. J Biol Chem. 2016; 291(35):18410–8. doi: 10.1074/jbc.M116.735647 PMID: 27365393
8. Pearce LR, Alton GR, Richter DT, Kath JC, Lingardo L, Chapman J, et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010; 431 (2):245–55. doi: 10.1042/BJ20101024 PMID: 20704563

9. Tolcher A, Goldman J, Patnaik A, Papadopoulos KP, Westwood P, Kelly CS, et al. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours. Eur J Cancer. 2014; 50(5):867–75. doi: 10.1016/j.ejca.2013.11.039 PMID: 24440085

10. Chouinard F, Turcotte C, Guan X, Larose MC, Poirier S, Bouchard L, et al. 2-Arachidonoyl-glycerol and arachidonic acid-stimulated neutrophils release antimicrobial effectors against E. coli, S. aureus, HSV-1, and RSV. J Leukoc Biol. 2013; 93(2):267–76. doi: 10.1189/jlb.0412200 PMID: 23242611

11. Chouinard F, Lefebvre JS, Navarro P, Bouchard L, Ferland C, Lalancette-Hebert M, et al. The endocannabinoid 2-arachidonoyl-glycerol activates human neutrophils: critical role of its hydrolysis and de novo leukotriene B₄ biosynthesis. J Immunol. 2011; 186(5):3188–96. doi: 10.4049/jimmunol.1002853 PMID: 21278347

12. Borgeat P, Picard S, Vallerand P, Bourgoin S, Odeimat A, Sirois P, et al. Automated on-line extraction and profiling of lipoxigenase products of arachidonic acid by high-performance liquid chromatography. Methods Enzymol. 1990; 187:98–116. PMID: 2122189

13. Shak S, Reich NO, Goldstein IM, Ortiz de Montellano PR. Leukotriene B₄ hydrolase: effects on purified enzyme and human polymorphonuclear leukocytes. J Biol Chem. 1985; 260 (24):13023–8. PMID: 2997155

14. Flamand N, Lefebvre J, Surette ME, Picard S, Borgeat P. Arachidonic acid regulates the translocation of 5-lipoxgenase to the nuclear membranes in human neutrophils. J Biol Chem. 2006; 281(1):129–36. doi: 10.1074/jbc.M506513200 PMID: 16275640

15. Flamand N, Picard S, Lemieux L, Pouliot M, Bourgoin SG, Borgeat P. Effects of pyrrophenone, an inhibitor of group IVA phospholipase A₂, on eicosanoid and PAF biosynthesis in human neutrophils. Br J Pharmacol. 2006; 149(4):385–92. doi: 10.1038/sj.bjp.0706879 PMID: 16967052

16. Flamand N, Surette ME, Picard S, Bourgoin S, Borgeat P. Cyclic AMP-mediated inhibition of 5-lipoxigenase translocation and leukotriene biosynthesis in human neutrophils. Mol Pharmacol. 2002; 62 (2):250–6. PMID: 12130675

17. Wetterholm A, Haeggstrom JZ, Samuelsson B, Yuan W, Munoz B, Wong CH. Potent and selective inhibitors of leukotriene A₄ hydrolase: effects on purified enzyme and human polymorphonuclear leukocytes. J Pharmacol Exp Ther. 1995; 275(1):31–7. PMID: 7562564

18. Krump E, Boudreault S, Surette ME, Borgeat P. Effect of GM-CSF on leukotriene B₄ synthesis in human neutrophils: facilitation of the priming effect by autologous plasma. Adv Exp Med Biol. 1997; 400B:583–7. PMID: 9547607

19. Surette ME, Dallaire N, Jean N, Picard S, Borgeat P. Mechanisms of the priming effect of lipopolysaccharides on the biosynthesis of leukotriene B₄ in chemotactic peptide-stimulated human neutrophils. FASEB J. 1998; 12(14):1521–31. PMID: 986761

20. Vainer GW, Saada A, Kania-Almog J, Amartely A, Bar-Tana J, Hertz R. PF-4708671 activates AMPK independently of p70S6K1 inhibition. PLoS One. 2014; 9(9):e107364. doi: 10.1371/journal.pone.0107364 PMID: 25202971

21. Arnold N, Koppula PR, Gull R, Luck C, Pulakat L. Regulation of cardiac expression of the diabetic marker microRNA miR-29. PLoS One. 2014; 9(7):e103284. doi: 10.1371/journal.pone.0103284 PMID: 25062042

22. Rajan MR, Fagerholm S, Jonsson C, Kjolhede P, Turkina MV, Straflors P. Phosphorylation of IRS1 at serine 307 in response to insulin in human adipocytes is not likely to be catalyzed by p70 ribosomal S6 kinase. PLoS One. 2013; 8(4):e59725. doi: 10.1371/journal.pone.0059725 PMID: 23565163

23. Shum M, Bellmann K, St-Pierre P, Marette A. Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice. Diabetologia. 2016; 59(3):592–603. doi: 10.1007/s00125-015-3839-6 PMID: 26733005

24. Choi HN, Jin HO, Kim JH, Hong SE, Kim HA, Kim EK, et al. Inhibition of S6K1 enhances glucose deprivation-induced cell death via downregulation of anti-apoptotic proteins in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 2013; 432(1):123–8. doi: 10.1016/j.bbrc.2013.01.074 PMID: 23376066

25. Grasso S, Tristante E, Saceda M, Carbonell P, Mayor-Lopez L, Carballo-Santana M, et al. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. Neoplasia. 2014; 16(10):845–55. doi: 10.1016/j.neo.2014.08.011 PMID: 25379221

26. Hong SE, Kim EK, Jin HO, Kim HA, Lee JK, Koh JS, et al. S6K1 inhibition enhances tamoxifen-induced cell death in MCF-7 cells through translational inhibition of Mcl-1 and survivin. Cell Biol Toxicol. 2013; 29(4):273–82. doi: 10.1007/s10565-013-9253-2 PMID: 23942996
27. Hong SE, Shin KS, Lee YH, Seo SK, Yun SM, Choe TB, et al. Inhibition of S6K1 enhances dichloroacetate-induced cell death. J Cancer Res Clin Oncol. 2015; 141(7):1171–9. doi: 10.1007/s00432-014-1887-9 PMID: 25471732

28. Khotskaya YB, Goverdhan A, Shen J, Ponz-Sarvis M, Chang SS, Hsu MC, et al. S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. Am J Transl Res. 2014; 6(4):361–76. PMID: 25075253

29. Qiu ZX, Sun RF, Mo XM, Li WM. The p70S6K Specific Inhibitor PF-4708671 Impedes Non-Small Cell Lung Cancer Growth. PLoS One. 2016; 11(1):e0147185. doi: 10.1371/journal.pone.0147185 PMID: 26771549

30. Song X, Dilly AK, Kim SY, Choudry HA, Lee YJ. Rapamycin-enhanced mitomycin C-induced apoptotic death is mediated through the S6K1-Bad-Bak pathway in peritoneal carcinomatosis. Cell Death Dis. 2014; 5:e1281. doi: 10.1038/cddis.2014.242 PMID: 24901052

31. Zhang Y, Wang Q, Chen L, Yang HS. Inhibition of p70S6K Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells. Mol Cancer Ther. 2015; 14(3):799–809. doi: 10.1158/1535-7163.MCT-14-0648 PMID: 25573956

32. Segatto I, Berton S, Sonego M, Massarut S, D’Andrea S, Perin T, et al. Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. J Mol Cell Biol. 2013; 5(6):428–31. doi: 10.1093/jmcb/mjt027 PMID: 23899505

33. Ben-Hur V, Denichenko P, Siegfried Z, Maimon A, Krainer A, Davidson B, et al. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep. 2013; 3(1):103–15. doi: 10.1016/j.celrep.2012.11.020 PMID: 23273915

34. Horrillo R, Gonzalez-Periz A, Martinez-Clemente M, Lopez-Parra M, Ferre N, Titos E, et al. 5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol. 2010; 184(7):3978–87. doi: 10.4049/jimmunol.0901355 PMID: 20907999

35. Mothe-Satney I, Filoux C, Amghar H, Pons C, Bourlier V, Galtzky J, et al. Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice. Diabetes. 2012; 61(9):2311–9. doi: 10.2337/db11-1455 PMID: 22688342

36. Li P, Oh da Y, Bandyopadhyay G, Lagakos WS, Talukdar S, Osborn O, et al. LTb4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015; 21(3):239–47. doi: 10.1038/nm.3800 PMID: 25706874

37. Spite M, Hellmann J, Tang Y, Mathis SP, Kosuri M, Bhatnagar A, et al. Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity. J Immunol. 2011; 187(4):1942–9. doi: 10.4049/jimmunol.1100196 PMID: 21742977

38. Powell WS, Gravelle F. Metabolism of arachidonic acid by peripheral and elicited rat polymorphonuclear leukocytes. Formation of 18- and 19-oxygenated dihydro metabolites of leukotriene B4. J Biol Chem. 1990; 265(16):9131–9. PMID: 2160957

39. Christmas P, Tolentino K, Primo V, Berry KZ, Murphy RC, Chen M, et al. Cytochrome P-450 4F18 is the leukotriene B4 omega-1/omega-2 hydroxylase in mouse polymorphonuclear leukocytes: identification as the functional orthologue of human polymorphonuclear leukocyte CYP4F3A in the down-regulation of responses to LTb4. J Biol Chem. 2006; 281(11):7189–96. doi: 10.1074/jbc.M513101200 PMID: 16980383